Certara (CERT) Set to Announce Earnings on Tuesday

Certara (NASDAQ:CERT) is scheduled to be announcing its earnings results after the market closes on Tuesday, August 6th. Analysts expect the company to announce earnings of $0.11 per share for the quarter. Certara has set its FY24 guidance at $0.41-0.46 EPS.Investors that are interested in registering for the company’s conference call can do so using this link.

Certara (NASDAQ:CERT) last issued its earnings results on Tuesday, May 7th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.01). The company had revenue of $96.65 million during the quarter, compared to analysts’ expectations of $94.48 million. Certara had a positive return on equity of 4.08% and a negative net margin of 17.02%. On average, analysts expect Certara to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Certara Price Performance

Shares of CERT opened at $15.26 on Monday. The firm has a fifty day simple moving average of $15.23 and a two-hundred day simple moving average of $16.56. The firm has a market cap of $2.45 billion, a PE ratio of -39.13, a P/E/G ratio of 5.39 and a beta of 1.52. The company has a current ratio of 3.26, a quick ratio of 3.26 and a debt-to-equity ratio of 0.27. Certara has a 1-year low of $11.81 and a 1-year high of $19.87.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on CERT shares. Barclays lowered their target price on Certara from $18.00 to $16.00 and set an “equal weight” rating on the stock in a report on Friday, June 28th. JMP Securities reiterated a “market perform” rating on shares of Certara in a research note on Wednesday, July 10th. Finally, KeyCorp dropped their price objective on shares of Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Seven research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Certara has an average rating of “Hold” and a consensus price target of $19.44.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.